NCT04636008View on ClinicalTrials.gov

Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 14, 2020

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Anti-PD-1 AntibodyRadiotherapyRectal CancerMSI-HMmr Deficiency
Interventions
DRUG

Sintilimab

Sintilimab+Hypofractionated radiotherapy

RADIATION

Hypofractionated Radiotherapy

Hypofractionated Radiotherapy

Trial Locations (1)

610041

RECRUITING

West China Hospital of Sichuan University, Chengdu

All Listed Sponsors
collaborator

First Affiliated Hospital of Chongqing Medical University

OTHER

collaborator

Yunnan Cancer Hospital

OTHER

collaborator

Sichuan Cancer Hospital and Research Institute

OTHER

collaborator

Chengdu Third People's Hospital

UNKNOWN

collaborator

The Affiliated Hospital Of Southwest Medical University

OTHER

lead

West China Hospital

OTHER